According to a recent LinkedIn post from Neuromod Devices Ltd, the company is highlighting a new partnership with Treble Health to expand access to its Lenire tinnitus treatment solution in the U.S. The post references a discussion featuring tinnitus care expert Dr. Gail B. Brenner, Au.D., in which she describes her background in tinnitus care and how the Lenire device is being used to provide what is described as clinically proven relief for patients.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The LinkedIn content indicates that Lenire will now be available in Philadelphia through The Tinnitus Treatment Center of Philadelphia with Dr. Gail B. Brenner, Au.D., and in Charlotte via Audiology & Hearing Services of Charlotte with Dr. Melissa Karp, Au.D. The post emphasizes Lenire’s positioning as an FDA-approved bimodal neuromodulation therapy supported by clinical trials.
For investors, this partnership suggests Neuromod Devices is pursuing a targeted geographic expansion strategy in the U.S. audiology and tinnitus-care market. By aligning with established clinical providers and a specialized tinnitus platform like Treble Health, the company appears to be strengthening its distribution network and clinical credibility, which could support increased device adoption and recurring revenue from clinical use. In a competitive hearing-care and neuromodulation space, this type of clinical partnership may enhance Neuromod’s positioning as a differentiated, evidence-based option for tinnitus management, potentially improving its long-term growth prospects if patient uptake and reimbursement pathways develop favorably.